6533b83afe1ef96bd12a7ab1

RESEARCH PRODUCT

In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.

Carlos MirandaFernando Gómez-contrerasLaurent LamarquePilar NavarroManuel Sánchez-morenoClotilde MarínOscar HuertasFrancisco OlmoJavier PitarchEnrique García-españaFrancisco Arrebola

subject

Chagas diseaseCell SurvivalTrypanosoma cruzichemistry.chemical_compoundMiceMicroscopy Electron TransmissionIn vivoDrug DiscoveryChlorocebus aethiopsmedicinePolyaminesAnimalsHumansChagas DiseaseEnzyme InhibitorsTrypanosoma cruziVero Cellschemistry.chemical_classificationMice Inbred BALB CbiologyChemistrySuperoxide Dismutasemedicine.diseasebiology.organism_classificationTrypanocidal AgentsIn vitroEnzymeBiochemistryLiverBenznidazoleVero cellMolecular MedicinePyrazolesFemalePolyaminemedicine.drug

description

The in vitro and in vivo anti- Trypanosoma cruzi activity of the pyrazole-containing macrobicyclic polyamine 1 and N-methyl- and N-benzyl-substituted monocyclic polyamines 2 and 3 was studied. Activity against both the acute and chronic phases of Chagas disease was considered. The compounds were more active against the parasite and less toxic against Vero cells than the reference drug benznidazole, but 1 and 2 were especially effective, where cryptand 1 was the most active, particularly in the chronic phase. The activity results found for these compounds were complemented and discussed by considering their inhibitory effect on the iron superoxide dismutase enzyme of the parasite, the nature of the metabolites excreted after treatment, and the ultrastructural alterations produced. A complementary histopathological analysis confirmed that the compounds tested were significantly less toxic to mammals than the reference drug and that 1 and 2 exhibited lower levels of damage than 3.

10.1021/jm2017144https://pubmed.ncbi.nlm.nih.gov/22443115